HY-148926 Search Results


hba1c reduction  (MedChemExpress)
90
MedChemExpress hba1c reduction
Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
Hba1c Reduction, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hba1c reduction/product/MedChemExpress
Average 90 stars, based on 1 article reviews
hba1c reduction - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control

Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Modification, Transplantation Assay

Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control

Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Standard Deviation

Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Standard Deviation